atopic dermatitis

JERSEY CITY, N.J., July 24, 2026 Organon (NYSE: OGN) presented new post hoc pooled Phase 3 data from the...

PARIS, France, July 24, 2026 Sanofi announced that it has discontinued the clinical development of amlitelimab for moderate-to-severe atopic...

QUÉBEC, Canada, July 21, 2026 Devonian Health Group has received Health Canada authorization to initiate a Phase II/III clinical...

FRIENDSWOOD, Texas, July 14, 2026 Castle Biosciences, Inc. has announced that its AdvanceAD-Tx™ test has received assay approval from...

WESTLAKE VILLAGE, Calif., July 8, 2026 Arcutis Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted...

PRINCETON, N.J., June 17, 2026 Bristol Myers Squibb (BMS) has announced that its Board of Directors has declared a...

WATERTOWN, Mass., June 17, 2026 Triveni Bio, a clinical-stage biotechnology company developing innovative antibody therapies for immunological and inflammatory...

INDIANAPOLIS, United States, June 9, 2026 Eli Lilly and Company has secured U.S. Food and Drug Administration (FDA) approval...

CHÂTILLON, France, June 8, 2026 DBV Technologies announced new positive clinical findings from its Phase 3 VITESSE study evaluating...

SAN FRANCISCO and BOSTON, May 27, 2026 Apogee Therapeutics announced a landmark $1.3 billion strategic financing collaboration with Blackstone...